Z79.631
Long term (current) use of antimetabolite agent
Clinical Classification Guidelines
Inclusion Terms
- Long term (current) use of 5-fluorouracil
- Long term (current) use of 6-mercaptopurine
- Long term (current) use of cytarabine
- Long term (current) use of methotrexate
Medical Intelligence & Overview
ICD-10 code Z79.631 pertains to the long-term or ongoing use of antimetabolite medications. These drugs are commonly prescribed for chronic conditions, especially certain types of cancer and autoimmune diseases. Antimetabolites interfere with cellular growth and reproduction, which helps to slow or halt disease progression. This classification includes well-known medications such as 5-fluorouracil, 6-mercaptopurine, cytarabine, and methotrexate. Understanding the nature of long-term antimetabolite therapy is essential for appreciating its role in disease management and potential impacts on health.
Causes & Symptoms
Clinical Causes: Chronic cancer treatment regimens (e.g., colorectal, leukemia, lymphoma, or other cancers) Management of autoimmune diseases (e.g., rheumatoid arthritis, psoriasis, inflammatory bowel disease) Condition requiring ongoing suppression of abnormal cell growth
Key Symptoms: Possible side effects related to medication use, including fatigue, nausea, or immune suppression Signs of bone marrow suppression such as easy bruising or bleeding Signs of infection due to lowered immune defenses Symptoms related to specific side effects of individual drugs (e.g., liver toxicity, mucositis)
Diagnostic & Treatment
Diagnosis Path: Diagnosis of long-term antimetabolite use is based on patient medical history and medication records. Healthcare providers review ongoing prescriptions, monitor for adverse effects, and perform laboratory tests such as blood counts and liver function tests regularly to assess tolerance and effects of the medication. Imaging or additional tests may be used to evaluate disease status.
Treatment Protocols: Long-term management involves regular monitoring by healthcare professionals to detect and mitigate adverse effects. Adjustments to medication dosage or regimen may be necessary based on patient response. Supportive care measures include managing side effects with medications, nutritional support, and infection prevention. In some cases, therapy may be temporarily paused or modified to improve patient safety.
Clinical Advice & FAQs
Billing Guidance
Is Z79.631 a billable ICD-10 code?
Yes, Z79.631 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report Z79.631?
Clinical documentation must specify the nature of Long term (current) use of antimetabolite agent and any associated comorbidities for accurate reporting.
Cite this Clinical Reference